ProCE Banner Activity

Approaches to CMV Immune Monitoring in Solid Organ Transplant Recipients

Clinical Thought

Here are the scenarios where I would consider CMV immune monitoring with CMV cell-mediated immunity assays to understand a patient’s risk of CMV infection, disease progression, and relapse post transplantation. 

Released: November 10, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Disclosure

Primary Author

Raymund Razonable, MD

Professor of Medicine
Division of Public Health, Infectious Diseases and Occupational Medicine
Mayo Clinic
Rochester, Minnesota 

Raymund Razonable, MD: consultant/advisor/speaker: Novartis; researcher: Gilead, Regeneron, Roche; independent contractor: Allovir.